BioSpace News Archive

BriaCell to Participate at Upcoming Conferences and Appoints Senior R&D Director - May 11, 2021

BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to participate in the following virtual conferences

May 11, 2021
·
4 min read
Business

Perrigo Reports First Quarter 2021 Financial Results From Continuing Operations

Perrigo Company plc, a leading global provider of Consumer Self-Care Products, announced financial results from continuing operations for the first quarter of fiscal year 2021 ended April 3, 2021.

May 11, 2021
·
34 min read
BioMidwest

Lilly and MiNA Therapeutics Announce saRNA Research Collaboration

Eli Lilly and Company and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA technology platform.

May 11, 2021
·
4 min read
Policy

FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, announced that the U.S. Food and Drug Administration has granted Fast Track designation to CERC-002 for treatment of hospitalized patients with COVID-19.

May 11, 2021
·
5 min read
Business

Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021.

May 11, 2021
·
1 min read
BioForest

Xtant Medical Files $150 Million Shelf Registration Statement

Xtant Medical Holdings, Inc., a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission.

May 11, 2021
·
5 min read
Business

Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights

Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned

May 11, 2021
·
7 min read
Deals

Foghorn Therapeutics Provides Corporate Update - May 11, 2021

Received IND clearance for FHD-609, a targeted protein degrader, which is being developed for the treatment of synovial sarcoma

May 11, 2021
·
4 min read
Drug Development

Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that it has reached 50% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis and chronic cough clinical study of its re-purposed drug NP-120.

May 11, 2021
·
4 min read
Drug Development

Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update

Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022 Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions

May 11, 2021
·
13 min read